Alemtuzumab is a medication used to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis. It is a monoclonal antibody that binds to CD52, a protein present on the surface of mature lymphocytes, but not on the stem cells from which these lymphocytes are derived. After treatment with alemtuzumab, these CD52-bearing lymphocytes are targeted for destruction.